Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimem containing Atazanavir (ATV)

Grants and Contracts Details

StatusFinished
Effective start/end date1/21/05 → 3/29/12

Funding

  • Bristol Myers Squibb Company: $6,921.00